1 2594 106 EPIGENETICS OF SCHIZOPHRENIA. SCHIZOPHRENIA (SCZ) IS A CHRONIC PSYCHOTIC DISORDER THAT CONTRIBUTES SIGNIFICANTLY TO DISABILITY, AFFECTING BEHAVIOR, THOUGHT, AND COGNITION. IT HAS LONG BEEN KNOWN THAT THERE IS A HERITABLE COMPONENT TO SCHIZOPHRENIA; STUDIES IN BOTH THE PRE-GENOMIC AND POST-GENOMIC ERA, HOWEVER, HAVE FAILED TO ELUCIDATE FULLY THE GENETIC BASIS FOR THIS COMPLEX DISEASE. EPIGENETIC PROCESSES - BROADLY, THOSE WHICH CONTRIBUTE TO CHANGES IN GENE EXPRESSION WITHOUT ALTERING THE GENETIC CODE ITSELF - MAY HELP TO UNDERSTAND BETTER THE MECHANISMS LEADING TO DEVELOPMENT OF SCZ. THE OBJECTIVE OF THIS REVIEW IS TO SYNTHESIZE CURRENT KNOWLEDGE OF THE EPIGENETIC MECHANISMS INVOLVED IN SCHIZOPHRENIA. SPECIFICALLY, DNA METHYLATION STUDIES IN BOTH PERIPHERAL AND POST-MORTEM BRAIN SAMPLES IN SCZ ARE REVIEWED, AS ARE EPIGENETIC MECHANISMS INCLUDING HISTONE MODIFICATION. THE PROMISING ROLE OF NON-CODING RNA INCLUDING MICRO-RNA (MIRNA) AND ITS ROLE AS A POTENTIAL DIAGNOSTIC AND THERAPEUTIC BIOMARKER IS OUTLINED, AS ARE EPIGENETIC AGE ACCELERATION AND TELOMERE SHORTENING. FINALLY, WE DISCUSS LIMITATIONS IN CURRENT KNOWLEDGE AND PROPOSE FUTURE RESEARCH DIRECTIONS. 2021 2 458 24 APPLYING MINIMALLY INVASIVE BIOMARKERS OF CHRONIC STRESS ACROSS COMPLEX ECOLOGICAL CONTEXTS. CHRONIC STRESS IS BOTH THEORETICALLY AND METHODOLOGICALLY CHALLENGING TO OPERATIONALIZE THROUGH BIOMARKERS. YET MINIMALLY INVASIVE, FIELD-FRIENDLY BIOMARKERS OF CHRONIC STRESS ARE VALUABLE IN RESEARCH LINKING BIOLOGY AND CULTURE, SEEKING TO UNDERSTAND DIFFERENTIAL PATTERNS OF HUMAN DEVELOPMENT ACROSS ECOLOGICAL CONTEXTS, AND EXPLORING THE EVOLUTION OF HUMAN SOCIALITY. FOR HUMAN BIOLOGISTS, A CENTRAL QUESTION IN MEASUREMENT AND INTERPRETATION OF BIOMARKERS IS HOW STRESS-RESPONSIVE PHYSIOLOGICAL SYSTEMS ARE REGULATED ACROSS DIVERSE HUMAN ECOLOGIES. THIS ARTICLE AIMS TO DESCRIBE A CONDITIONAL TOOLKIT FOR HUMAN BIOLOGISTS INTERESTED IN THE STUDY OF CHRONIC STRESS, HIGHLIGHTING A MIX OF LONGSTANDING AND NOVEL BIOMARKERS, WITH SPECIAL FOCUS ON HAIR/FINGERNAIL CORTISOL, LATENT HERPESVIRUS ANTIBODIES, ALLOSTATIC LOAD INDICES, AND SERIAL/AMBULATORY DATA COLLECTION APPROACHES. FUTURE TRENDS IN CHRONIC STRESS BIOMARKER RESEARCH, INCLUDING EPIGENETIC APPROACHES, ARE BRIEFLY CONSIDERED. THIS OVERVIEW CONSIDERS: (1) CHALLENGES IN SEPARATING A DISTINCTLY PSYCHOSOCIAL DIMENSION OF CHRONIC STRESS FROM ADVERSITY MORE BROADLY; (2) ESSENTIAL CHARACTERISTICS OF HUMAN ECOLOGY THAT SHAPE INTERPRETATION; (3) RETROSPECTIVE VS. LONGITUDINAL SAMPLING; (4) THE ROLE OF AGE, DEVELOPMENTAL EFFECTS, AND LOCAL BIOLOGIES; (5) DIFFERENT TIMESCALES OF CHRONICITY; AND (6) THE ROLE OF CULTURE. 2022 3 5482 26 RETHINKING GENETIC MODELS OF ASTHMA: THE ROLE OF ENVIRONMENTAL MODIFIERS. ASTHMA IS A COMMON, CHRONIC DISEASE WITH A COMPLEX ETIOLOGY. TO DATE, MORE THAN 35 GENES HAVE BEEN ASSOCIATED WITH ASTHMA OR RELATED PHENOTYPES IN MULTIPLE POPULATIONS, BUT NONE OF THEM HAS BEEN SHOWN TO CONTRIBUTE TO RISK IN ALL POPULATIONS STUDIED. WE SUGGEST THAT GENETIC SUSCEPTIBILITY IS BOTH CONTEXT DEPENDENT AND DEVELOPMENTALLY REGULATED, AND THAT IGNORING THE ENVIRONMENTAL CONTEXT WILL MISS MANY IMPORTANT ASSOCIATIONS AND CLUES TO PATHOGENESIS. WE DEFINE 'ENVIRONMENT' BROADLY TO INCLUDE THE IN UTERO ENVIRONMENT, MATERNAL AFFECTION STATUS AND SEX, AND PROPOSE THAT EPIGENETIC MECHANISMS ARE THE LINK BETWEEN OUR GENES AND OUR ENVIRONMENT. 2005 4 2528 25 EPIGENETICS AS A KEY LINK BETWEEN PSYCHOSOCIAL STRESS AND AGING: CONCEPTS, EVIDENCE, MECHANISMS . PSYCHOSOCIAL STRESS-ESPECIALLY WHEN CHRONIC, EXCESSIVE, OR OCCURRING EARLY IN LIFE-HAS BEEN ASSOCIATED WITH ACCELERATED AGING AND INCREASED DISEASE RISK. WITH RAPID AGING OF THE WORLD POPULATION, THE NEED TO ELUCIDATE THE UNDERLYING MECHANISMS IS PRESSING, NOW MORE SO THAN EVER. AMONG MOLECULAR MECHANISMS LINKING STRESS AND AGING, THE PRESENT ARTICLE REVIEWS EVIDENCE ON THE ROLE OF EPIGENETICS, BIOCHEMICAL PROCESSES THAT CAN BE SET INTO MOTION BY STRESSORS AND IN TURN INFLUENCE GENOMIC FUNCTION AND COMPLEX PHENOTYPES, INCLUDING AGING-RELATED OUTCOMES. THE ARTICLE FURTHER PROVIDES A CONCEPTUAL MECHANISTIC FRAMEWORK ON HOW STRESS MAY DRIVE EPIGENETIC CHANGES AT SUSCEPTIBLE GENOMIC SITES, THEREBY EXERTING SYSTEMS-LEVEL EFFECTS ON THE AGING EPIGENOME WHILE ALSO REGULATING THE EXPRESSION OF MOLECULES IMPLICATED IN AGING-RELATED PROCESSES. THIS EMERGING EVIDENCE, TOGETHER WITH WORK EXAMINING RELATED BIOLOGICAL PROCESSES, BEGINS TO SHED LIGHT ON THE EPIGENETIC AND, MORE BROADLY, MOLECULAR UNDERPINNINGS OF THE LONG-HYPOTHESIZED CONNECTION BETWEEN STRESS AND AGING. . 2019 5 3852 30 IS MATERNAL MICROBIAL METABOLISM AN EARLY-LIFE DETERMINANT OF HEALTH? MOUNTING EVIDENCE SUGGESTS THAT ENVIRONMENTAL STRESS EXPERIENCED IN UTERO (FOR EXAMPLE, MATERNAL NUTRITIONAL DEFICITS) ESTABLISHES A PREDISPOSITION IN THE NEWBORN TO THE DEVELOPMENT OF CHRONIC DISEASES LATER IN LIFE. THIS CONCEPT IS OFTEN REFERRED TO AS THE "FETAL ORIGINS HYPOTHESIS" OR "DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE". SINCE ITS FIRST PROPOSAL, EPIGENETICS HAS EMERGED AS AN UNDERLYING MECHANISM EXPLAINING HOW ENVIRONMENTAL CUES BECOME GESTATIONALLY "ENCODED". MANY OF THE ENZYMES THAT IMPART AND MAINTAIN EPIGENETIC MODIFICATIONS ARE HIGHLY SENSITIVE TO NUTRIENT AVAILABILITY, WHICH CAN BE INFLUENCED BY THE METABOLIC ACTIVITIES OF THE INTESTINAL MICROBIOTA. THEREFORE, THE MATERNAL MICROBIOME HAS THE POTENTIAL TO INFLUENCE EPIGENETICS IN UTERO AND MODULATE OFFSPRING'S LONG-TERM HEALTH TRAJECTORIES. HERE WE SUMMARIZE THE CURRENT UNDERSTANDING OF THE INTERACTIONS THAT OCCUR BETWEEN THE MATERNAL GUT MICROBIOME AND THE ESSENTIAL NUTRIENT CHOLINE, THAT IS NOT ONLY REQUIRED FOR FETAL DEVELOPMENT AND EPIGENETIC REGULATION BUT IS ALSO A GROWTH SUBSTRATE FOR SOME MICROBES. BACTERIA ABLE TO METABOLIZE CHOLINE BENEFIT FROM THE PRESENCE OF THIS NUTRIENT AND COMPETE WITH THE HOST FOR ITS ACCESS, WHICH UNDER EXTREME CONDITIONS MAY ELICIT SIGNATURES OF CHOLINE DEFICIENCY. ANOTHER CONSEQUENCE OF BACTERIAL CHOLINE METABOLISM IS THE ACCUMULATION OF THE PRO-INFLAMMATORY, PRO-THROMBOTIC METABOLITE TRIMETHYLAMINE-N-OXIDE (TMAO). FINALLY, WE DISCUSS HOW THESE DIFFERENT FACETS OF MICROBIAL CHOLINE METABOLISM MAY INFLUENCE INFANT DEVELOPMENT AND HEALTH TRAJECTORIES VIA EPIGENETIC MECHANISMS AND MORE BROADLY PLACE A CALL TO ACTION TO BETTER UNDERSTAND HOW MATERNAL MICROBIAL METABOLISM CAN SHAPE THEIR OFFSPRING'S PROPENSITY TO CHRONIC DISEASE DEVELOPMENT LATER IN LIFE. 2018 6 2586 30 EPIGENETICS OF PAIN MEDIATORS. PURPOSE OF REVIEW: THE FIELD OF EPIGENETICS CONTINUES ITS INFLUENTIAL RISE AS A MEANS TO BETTER UNDERSTAND AN ORGANISM'S UNIQUE DEVELOPMENTAL IDENTITY OVER A LIFESPAN. WHEREAS A GENOME IS CONSTANT AND UNCHANGING, AN EPIGENOME IS DYNAMIC AND ALTERABLE. EPIGENETIC CHANGES ARE IN RESPONSE TO INNUMERABLE INTERNAL AND EXTERNAL INFLUENCES INCLUDING ENVIRONMENTAL CHANGES SUCH AS DIET, EXERCISE, DISEASE, TOXINS, AND STRESS. EPIGENETICS IS OF PARTICULAR INTEREST IN THE MEDICAL RESEARCH COMMUNITY BOTH FOR THE POTENTIAL TO CAUSE DISEASE AND AS A TARGET FOR THERAPEUTIC INTERVENTIONS. THIS ARTICLE PROVIDES A SUCCINCT EXPLANATION OF THE POTENTIAL FOR EPIGENETICS TO INFLUENCE THE UNDERSTANDING OF PAIN AS WELL AS A REVIEW OF RELEVANT RESEARCH ON THE TOPIC. RECENT FINDINGS: STUDIES ON EPIGENETICS AND PAIN REMAIN LARGELY PRECLINICAL AND INVESTIGATE THE THEORETICAL ABILITY OF EPIGENETICS TO ALTER THE NOCICEPTIVE PATHWAYS BOTH IN THE PERIPHERY AND CENTRALLY. SIGNIFICANT EVIDENCE NOW EXISTS FOR THE ABILITY OF EPIGENETICS TO MODIFY BROADLY CATEGORIZED PAIN TYPES, INCLUDING INFLAMMATORY, NEUROPATHIC, VISCERAL, AND CANCER RELATED. SUMMARY: BOTH PATIENTS AND PROVIDERS RECOGNIZE THAT NOVEL MEDICATIONS FOR THE TREATMENT OF BOTH ACUTE AND CHRONIC PAIN CONDITIONS ARE SORELY NEEDED. THE UNDERSTANDING OF EPIGENETICS AND ITS INFLUENCE ON NOCICEPTION REMAINS IN RELATIVE INFANCY BUT EARLY EVIDENCE IS STRONG FOR POTENTIAL THERAPEUTIC BENEFITS TO TREAT THESE CONDITIONS. 2018 7 5926 38 TARGETING EPIGENETIC MECHANISMS FOR CHRONIC PAIN: A VALID APPROACH FOR THE DEVELOPMENT OF NOVEL THERAPEUTICS. CHRONIC PAIN IS A MULTIFACETED AND COMPLEX CONDITION. BROADLY CLASSIFIED INTO SOMATIC, VISCERAL, OR NEUROPATHIC PAIN, IT IS POORLY MANAGED DESPITE ITS PREVALENCE. CURRENT DRUGS USED FOR THE TREATMENT OF CHRONIC PAIN ARE LIMITED BY TOLERANCE WITH LONG-TERM USE, ABUSE POTENTIAL, AND MULTIPLE ADVERSE SIDE EFFECTS. THE PERSISTENT NATURE OF PAIN SUGGESTS THAT EPIGENETIC MACHINERY MAY BE A CRITICAL FACTOR DRIVING CHRONIC PAIN. IN THIS REVIEW, WE DISCUSS THE LATEST INSIGHTS INTO EPIGENETIC PROCESSES, INCLUDING DNA METHYLATION, HISTONE MODIFICATIONS, AND MICRORNAS, AND WE DESCRIBE THEIR INVOLVEMENT IN THE PATHOPHYSIOLOGY OF CHRONIC PAIN AND WHETHER EPIGENETIC MODIFICATIONS COULD BE APPLIED AS FUTURE THERAPEUTIC TARGETS FOR CHRONIC PAIN. WE PROVIDE EVIDENCE FROM EXPERIMENTAL MODELS AND TRANSLATIONAL RESEARCH IN HUMAN TISSUE THAT HAVE ENHANCED OUR UNDERSTANDING OF EPIGENETIC PROCESSES MEDIATING NOCICEPTION, AND WE THEN SPECULATE ON THE POTENTIAL FUTURE USE OF MORE SPECIFIC AND SELECTIVE AGENTS THAT TARGET EPIGENETIC MECHANISMS TO ATTENUATE PAIN. 2016 8 5513 29 RICHTER SYNDROME: NOVEL INSIGHTS INTO THE BIOLOGY OF TRANSFORMATION. ALTHOUGH THE GENETIC LANDSCAPE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) HAS BEEN BROADLY PROFILED BY LARGE-SCALE SEQUENCING STUDIES PERFORMED OVER THE PAST DECADE, THE MOLECULAR BASIS OF THE TRANSFORMATION OF CLL INTO AGGRESSIVE LYMPHOMA, OR RICHTER SYNDROME (RS), HAS REMAINED INCOMPLETELY CHARACTERIZED. RECENT ADVANCES IN COMPUTATIONAL METHODS OF CLONAL DECONVOLUTION, AS WELL AS EXTENSIVE SAMPLE COLLECTION EFFORTS IN THIS RAPIDLY PROGRESSIVE MALIGNANCY, HAVE NOW ENABLED COMPREHENSIVE ANALYSIS OF PAIRED CLL AND RS SAMPLES AND HAVE LED TO MULTIPLE NEW STUDIES INVESTIGATING THE GENETIC, TRANSCRIPTOMIC, AND EPIGENETIC ORIGINS OF RS. IN PARALLEL, NEW GENETICALLY ENGINEERED AND XENOGRAFT MOUSE MODELS HAVE PROVIDED THE OPPORTUNITY FOR GLEANING FRESH BIOLOGICAL AND MECHANISTIC INSIGHTS INTO RS DEVELOPMENT AND STEPWISE EVOLUTION FROM ANTECEDENT CLL. ALTOGETHER, THESE STUDIES HAVE DEFINED RS DRIVER LESIONS AND CLL RISK LESIONS AND IDENTIFIED PATHWAYS DYSREGULATED IN TRANSFORMATION. MOREOVER, UNIQUE MOLECULAR SUBTYPES OF RS HAVE BEEN REVEALED, INCLUDING A DISEASE MARKED BY PROFOUND GENOMIC INSTABILITY WITH CHROMOTHRIPSIS/CHROMOPLEXY AND WHOLE GENOME DUPLICATION. NOVEL PROFILING APPROACHES, INCLUDING SINGLE-CELL DNA AND TRANSCRIPTOME SEQUENCING OF RS BIOPSY SPECIMENS AND CELL-FREE DNA PROFILING OF PATIENT PLASMA, DEMONSTRATE PROMISE FOR THE TIMELY IDENTIFICATION OF RS CLONES AND MAY TRANSLATE TO NONINVASIVE IDENTIFICATION AND EARLY DIAGNOSIS OF RS. THIS REVIEW SUMMARIZES THE RECENT SCIENTIFIC ADVANCES IN RS AND SUPPORTS THE INTEGRATED STUDY OF HUMAN GENOMICS WITH MOUSE MODELING TO PROVIDE AN ADVANCED UNDERSTANDING OF THE BIOLOGICAL UNDERPINNINGS OF TRANSFORMATION. THESE RECENT STUDIES HAVE MAJOR IMPLICATIONS FOR MUCH-NEEDED NOVEL THERAPEUTIC STRATEGIES FOR THIS STILL LARGELY INCURABLE MALIGNANCY. 2023 9 980 26 CHRONIC PAIN: EMERGING EVIDENCE FOR THE INVOLVEMENT OF EPIGENETICS. EPIGENETIC PROCESSES, SUCH AS HISTONE MODIFICATIONS AND DNA METHYLATION, HAVE BEEN ASSOCIATED WITH MANY NEURAL FUNCTIONS INCLUDING SYNAPTIC PLASTICITY, LEARNING, AND MEMORY. HERE, WE CRITICALLY EXAMINE EMERGING EVIDENCE LINKING EPIGENETIC MECHANISMS TO THE DEVELOPMENT OR MAINTENANCE OF CHRONIC PAIN STATES. ALTHOUGH IN ITS INFANCY, RESEARCH IN THIS AREA POTENTIALLY UNIFIES SEVERAL PATHOPHYSIOLOGICAL PROCESSES UNDERPINNING ABNORMAL PAIN PROCESSING AND OPENS UP A DIFFERENT AVENUE FOR THE DEVELOPMENT OF NOVEL ANALGESICS. 2012 10 357 32 ALTERNATIVE MODELS FOR TRANSGENERATIONAL EPIGENETIC INHERITANCE: MOLECULAR PSYCHIATRY BEYOND MICE AND MAN. MENTAL ILLNESS REMAINS THE GREATEST CHRONIC HEALTH BURDEN GLOBALLY WITH FEW IN-ROADS HAVING BEEN MADE DESPITE SIGNIFICANT ADVANCES IN GENOMIC KNOWLEDGE IN RECENT DECADES. THE FIELD OF PSYCHIATRY IS CONSTANTLY CHALLENGED TO BRING NEW APPROACHES AND TOOLS TO ADDRESS AND TREAT THE NEEDS OF VULNERABLE INDIVIDUALS AND SUBPOPULATIONS, AND THAT HAS TO BE SUPPORTED BY A CONTINUOUS GROWTH IN KNOWLEDGE. THE MAJORITY OF NEUROPSYCHIATRIC SYMPTOMS REFLECT COMPLEX GENE-ENVIRONMENT INTERACTIONS, WITH EPIGENETICS BRIDGING THE GAP BETWEEN GENETIC SUSCEPTIBILITY AND ENVIRONMENTAL STRESSORS THAT TRIGGER DISEASE ONSET AND DRIVE THE ADVANCEMENT OF SYMPTOMS. IT HAS MORE RECENTLY BEEN DEMONSTRATED IN PRECLINICAL MODELS THAT EPIGENETICS UNDERPINS THE TRANSGENERATIONAL INHERITANCE OF STRESS-RELATED BEHAVIOURAL PHENOTYPES IN BOTH PATERNAL AND MATERNAL LINEAGES, PROVIDING FURTHER SUPPORTING EVIDENCE FOR HERITABILITY IN HUMANS. HOWEVER, UNBIASED PROSPECTIVE STUDIES OF THIS NATURE ARE PRACTICALLY IMPOSSIBLE TO CONDUCT IN HUMANS SO PRECLINICAL MODELS REMAIN OUR BEST OPTION FOR RESEARCHING THE MOLECULAR PATHOPHYSIOLOGIES UNDERLYING MANY NEUROPSYCHIATRIC CONDITIONS. WHILE RODENTS WILL REMAIN THE DOMINANT MODEL SYSTEM FOR PRECLINICAL STUDIES (ESPECIALLY FOR ADDRESSING COMPLEX BEHAVIOURAL PHENOTYPES), THERE IS SCOPE TO EXPAND CURRENT RESEARCH OF THE MOLECULAR AND EPIGENETIC PATHOLOGIES BY USING INVERTEBRATE MODELS. HERE, WE WILL DISCUSS THE UTILITY AND ADVANTAGES OF TWO ALTERNATIVE MODEL ORGANISMS-CAENORHABDITIS ELEGANS AND DROSOPHILA MELANOGASTER-AND SUMMARISE THE COMPELLING INSIGHTS OF THE EPIGENETIC REGULATION OF TRANSGENERATIONAL INHERITANCE THAT ARE POTENTIALLY RELEVANT TO HUMAN PSYCHIATRY. 2021 11 2209 19 EPIGENETIC MODIFICATIONS AND OBSESSIVE-COMPULSIVE DISORDER: WHAT DO WE KNOW? OBSESSIVE-COMPULSIVE DISORDER (OCD) IS A CHRONIC, SEVERE DISABLING NEUROPSYCHIATRIC DISORDER WHOSE PATHOPHYSIOLOGY IS NOT YET WELL DEFINED. GENERALLY, THE SYMPTOM ONSET OCCURS DURING PRE-ADULT LIFE AND AFFECTS SUBJECTS IN DIFFERENT LIFE ASPECTS, INCLUDING PROFESSIONAL AND SOCIAL RELATIONSHIPS. ALTHOUGH ROBUST EVIDENCE INDICATES THE PRESENCE OF GENETIC FACTORS IN THE ETIOPATHOLOGY OF OCD, THE ENTIRELY MECHANISMS ARE NOT TOTALLY CLARIFIED. THUS, THE POSSIBLE INTERACTIONS BETWEEN GENES AND ENVIRONMENTAL RISK FACTORS MEDIATED BY EPIGENETIC MECHANISMS SHOULD BE SOUGHT. THEREFORE, WE PROVIDE A REVIEW OF GENETIC AND EPIGENETIC MECHANISMS RELATED TO OCD WITH A DEEP FOCUS ON THE REGULATION OF CRITICAL GENES OF THE CENTRAL NERVOUS SYSTEM SEEKING POSSIBLE POTENTIAL BIOMARKERS. 2023 12 2454 27 EPIGENETIC TARGETING OF HISTONE DEACETYLASES IN DIAGNOSTICS AND TREATMENT OF DEPRESSION. DEPRESSION IS A HIGHLY PREVALENT, DISABLING, AND OFTEN CHRONIC ILLNESS THAT PLACES SUBSTANTIAL BURDENS ON PATIENTS, FAMILIES, HEALTHCARE SYSTEMS, AND THE ECONOMY. A SUBSTANTIAL MINORITY OF PATIENTS ARE UNRESPONSIVE TO CURRENT THERAPIES, SO THERE IS AN URGENT NEED TO DEVELOP MORE BROADLY EFFECTIVE, ACCESSIBLE, AND TOLERABLE THERAPIES. PHARMACOLOGICAL REGULATION OF HISTONE ACETYLATION LEVEL HAS BEEN INVESTIGATED AS ONE POTENTIAL CLINICAL STRATEGY. HISTONE ACETYLATION STATUS IS CONSIDERED A POTENTIAL DIAGNOSTIC BIOMARKER FOR DEPRESSION, WHILE INHIBITORS OF HISTONE DEACETYLASES (HDACS) HAVE GARNERED INTEREST AS NOVEL THERAPEUTICS. THIS REVIEW DESCRIBES RECENT ADVANCES IN OUR KNOWLEDGE OF HISTONE ACETYLATION STATUS IN DEPRESSION AND THE THERAPEUTIC POTENTIAL OF HDAC INHIBITORS. 2021 13 1352 29 DEVELOPMENT AND APPLICATION OF THE ADVERSE OUTCOME PATHWAY FRAMEWORK FOR UNDERSTANDING AND PREDICTING CHRONIC TOXICITY: I. CHALLENGES AND RESEARCH NEEDS IN ECOTOXICOLOGY. TO ELUCIDATE THE EFFECTS OF CHEMICALS ON POPULATIONS OF DIFFERENT SPECIES IN THE ENVIRONMENT, EFFICIENT TESTING AND MODELING APPROACHES ARE NEEDED THAT CONSIDER MULTIPLE STRESSORS AND ALLOW RELIABLE EXTRAPOLATION OF RESPONSES ACROSS SPECIES. AN ADVERSE OUTCOME PATHWAY (AOP) IS A CONCEPT THAT PROVIDES A FRAMEWORK FOR ORGANIZING KNOWLEDGE ABOUT THE PROGRESSION OF TOXICITY EVENTS ACROSS SCALES OF BIOLOGICAL ORGANIZATION THAT LEAD TO ADVERSE OUTCOMES RELEVANT FOR RISK ASSESSMENT. IN THIS PAPER, WE FOCUS ON EXPLORING HOW THE AOP CONCEPT CAN BE USED TO GUIDE RESEARCH AIMED AT IMPROVING BOTH OUR UNDERSTANDING OF CHRONIC TOXICITY, INCLUDING DELAYED TOXICITY AS WELL AS EPIGENETIC AND TRANSGENERATIONAL EFFECTS OF CHEMICALS, AND OUR ABILITY TO PREDICT ADVERSE OUTCOMES. A BETTER UNDERSTANDING OF THE INFLUENCE OF SUBTLE TOXICITY ON INDIVIDUAL AND POPULATION FITNESS WOULD SUPPORT A BROADER INTEGRATION OF SUBLETHAL ENDPOINTS INTO RISK ASSESSMENT FRAMEWORKS. DETAILED MECHANISTIC KNOWLEDGE WOULD FACILITATE THE DEVELOPMENT OF ALTERNATIVE TESTING METHODS AS WELL AS HELP PRIORITIZE HIGHER TIER TOXICITY TESTING. WE ARGUE THAT TARGETED DEVELOPMENT OF AOPS SUPPORTS BOTH OF THESE ASPECTS BY PROMOTING THE ELUCIDATION OF MOLECULAR MECHANISMS AND THEIR CONTRIBUTION TO RELEVANT TOXICITY OUTCOMES ACROSS BIOLOGICAL SCALES. WE FURTHER DISCUSS INFORMATION REQUIREMENTS AND CHALLENGES IN APPLICATION OF AOPS FOR CHEMICAL- AND SITE-SPECIFIC RISK ASSESSMENT AND FOR EXTRAPOLATION ACROSS SPECIES. WE PROVIDE RECOMMENDATIONS FOR POTENTIAL EXTENSION OF THE AOP FRAMEWORK TO INCORPORATE INFORMATION ON EXPOSURE, TOXICOKINETICS AND SITUATION-SPECIFIC ECOLOGICAL CONTEXTS, AND DISCUSS COMMON INTERFACES THAT CAN BE EMPLOYED TO COUPLE AOPS WITH COMPUTATIONAL MODELING APPROACHES AND WITH EVOLUTIONARY LIFE HISTORY THEORY. THE EXTENDED AOP FRAMEWORK CAN SERVE AS A VENUE FOR INTEGRATION OF KNOWLEDGE DERIVED FROM VARIOUS SOURCES, INCLUDING EMPIRICAL DATA AS WELL AS MOLECULAR, QUANTITATIVE AND EVOLUTIONARY-BASED MODELS DESCRIBING SPECIES RESPONSES TO TOXICANTS. THIS WILL ALLOW A MORE EFFICIENT APPLICATION OF AOP KNOWLEDGE FOR QUANTITATIVE CHEMICAL- AND SITE-SPECIFIC RISK ASSESSMENT AS WELL AS FOR EXTRAPOLATION ACROSS SPECIES IN THE FUTURE. 2015 14 1279 28 DE NOVO MUTATIONS IDENTIFIED BY WHOLE-GENOME SEQUENCING IMPLICATE CHROMATIN MODIFICATIONS IN OBSESSIVE-COMPULSIVE DISORDER. OBSESSIVE-COMPULSIVE DISORDER (OCD) IS A CHRONIC ANXIETY DISORDER WITH A SUBSTANTIAL GENETIC BASIS AND A BROADLY UNDISCOVERED ETIOLOGY. RECENT STUDIES OF DE NOVO MUTATION (DNM) EXOME-SEQUENCING STUDIES FOR OCD HAVE REINFORCED THE HYPOTHESIS THAT RARE VARIATION CONTRIBUTES TO THE RISK. WE PERFORMED, TO OUR KNOWLEDGE, THE FIRST WHOLE-GENOME SEQUENCING ON 53 PARENT-OFFSPRING FAMILIES WITH OFFSPRING AFFECTED WITH OCD TO INVESTIGATE ALL RARE DE NOVO VARIANTS AND INSERTIONS/DELETIONS. WE OBSERVED HIGHER MUTATION RATES IN PROMOTER-ANCHORED CHROMATIN LOOPS (EMPIRICAL P = 0.0015) AND REGIONS WITH HIGH FREQUENCIES OF HISTONE MARKS (EMPIRICAL P = 0.0001). MUTATIONS AFFECTING CODING REGIONS WERE SIGNIFICANTLY ENRICHED WITHIN COEXPRESSION MODULES OF GENES INVOLVED IN CHROMATIN MODIFICATION DURING HUMAN BRAIN DEVELOPMENT. FOUR GENES-SETD5, KDM3B, ASXL3, AND FBL-HAD STRONG AGGREGATED EVIDENCE AND FUNCTIONALLY CONVERGED ON TRANSCRIPTION'S EPIGENETIC REGULATION, SUGGESTING AN IMPORTANT OCD RISK MECHANISM. OUR DATA CHARACTERIZED DIFFERENT GENOME-WIDE DNMS AND HIGHLIGHTED THE CONTRIBUTION OF CHROMATIN MODIFICATION IN THE ETIOLOGY OF OCD. 2022 15 6802 22 [EPIGENETIC MECHANISMS IN MODELS OF CHRONIC PAIN - A TARGET FOR NOVEL THERAPY?]. EVIDENCE OF EPIGENETICS' ROLE IN PAIN RESPONSE IS ACCUMULATING IN RECENT YEARS. TIGHTLY REGULATED EPIGENETIC ALTERATIONS ON DNA AND HISTONES IN THE SENSORY CIRCUIT SHAPE THE PHYSIOLOGICAL RESPONSE TO INJURY. ALTERING THOSE EPIGENETIC PROCESSES HINDERS THERAPEUTIC POTENTIAL IN PAIN. THIS REVIEW PROVIDES AN OVERVIEW OF EPIGENOMIC MODIFICATION IN THE DEVELOPMENT OF CHRONIC PAIN, AND SUMMARIZES THE THERAPEUTIC POTENTIAL TO ALTER EPIGENETIC PROCESSES. 2018 16 3900 29 LATEST INSIGHTS INTO PATHOGENESIS OF MYCOSIS FUNGOIDES AND CUTANEOUS T-CELL LYMPHOMA. CUTANEOUS T-CELL LYMPHOMA (CTCL) IS A RARE BUT INCREASING MALIGNANCY WHOSE PROTEAN MANIFESTATIONS NECESSARILY PRESENT IN THE INTEGUMENT, BUT CAN ALSO SPREAD TO INVOLVE BLOOD, LYMPH NODES AND INTERNAL ORGANS. WE HAVE DEVELOPED EFFICACIOUS AND VARIED THERAPIES TO TREAT EARLY AND ADVANCED STAGE DISEASE, BUT THERE ARE STILL MANY WHO SUFFER TREMENDOUSLY FROM THIS ILLNESS. ALTHOUGH THE PATHOGENESIS OF THIS CANCER REMAINS FRUSTRATINGLY ELUSIVE, OVER THE LAST 200 YEARS WE HAVE GENERATED A ROBUST BODY OF EVIDENCE THAT POINTS TOWARD POSSIBLE SINGULAR AS WELL AS MULTIFACTORIAL ETIOLOGIES. COMBINING THE HISTORICAL HYPOTHESES WHICH HAVE FOCUSED UPON THE CONCEPT OF INFECTIOUS CAUSES, INCLUDING CARCINOGENIC GENOMIC VIRAL INTEGRATION AND BACTERIAL SUPERANTIGENIC CHRONIC STIMULATION AS WELL AS INDUSTRIAL/OCCUPATIONAL EXPOSURE, ALONG WITH THE MORE RECENT REVELATIONS OF BOTH GENETIC AND EPIGENETIC ALTERATION AND IMMUNE DYSREGULATION, WE ARE CLOSER THAN EVER TO UNDERSTANDING THE ETIOLOGY OF CTCL. IT IS THROUGH THIS KNOWLEDGE AND CONTINUED RESEARCH EFFORTS THAT WE WILL BE ABLE TO BETTER DIAGNOSE, TREAT, AND POTENTIALLY PREVENT OR CURE CTCL. 2017 17 4914 33 PAIN VULNERABILITY: A NEUROBIOLOGICAL PERSPECTIVE. THERE ARE MANY KNOWN RISK FACTORS FOR CHRONIC PAIN CONDITIONS, YET THE BIOLOGICAL UNDERPINNINGS THAT LINK THESE FACTORS TO ABNORMAL PROCESSING OF PAINFUL SIGNALS ARE ONLY JUST BEGINNING TO BE EXPLORED. THIS REVIEW WILL DISCUSS THE POTENTIAL MECHANISMS THAT HAVE BEEN PROPOSED TO UNDERLIE VULNERABILITY AND RESILIENCE TOWARD DEVELOPING CHRONIC PAIN. PARTICULAR FOCUS WILL BE GIVEN TO GENETIC AND EPIGENETIC PROCESSES, PRIMING EFFECTS ON A CELLULAR LEVEL, AND ALTERATIONS IN BRAIN NETWORKS CONCERNED WITH REWARD, MOTIVATION/LEARNING AND DESCENDING MODULATORY CONTROL. ALTHOUGH RESEARCH IN THIS AREA IS STILL IN ITS INFANCY, A BETTER UNDERSTANDING OF HOW PAIN VULNERABILITY EMERGES HAS THE POTENTIAL TO HELP IDENTIFY INDIVIDUALS AT RISK AND MAY OPEN UP NEW THERAPEUTIC AVENUES. 2014 18 6322 26 THE ROLE FOR EPIGENETIC MODIFICATIONS IN PAIN AND ANALGESIA RESPONSE. PAIN REMAINS A POORLY UNDERSTOOD AND MANAGED SYMPTOM. A LIMITED MECHANISTIC UNDERSTANDING OF INTERINDIVIDUAL DIFFERENCES IN PAIN AND ANALGESIA RESPONSE SHAPES CURRENT APPROACHES TO ASSESSMENT AND TREATMENT. OPPORTUNITIES EXIST TO IMPROVE PAIN CARE THROUGH INCREASED UNDERSTANDING OF HOW DYNAMIC EPIGENOMIC REMODELING SHAPES INJURY, ILLNESS, PAIN, AND TREATMENT RESPONSE. TIGHTLY REGULATED ALTERATIONS OF THE DNA-HISTONE CHROMATIN COMPLEX ENABLE CELLS TO CONTROL TRANSCRIPTION, REPLICATION, GENE EXPRESSION, AND PROTEIN PRODUCTION. PATHOLOGICAL ALTERATIONS TO CHROMATIN SHAPE THE ABILITY OF THE CELL TO RESPOND TO PHYSIOLOGIC AND ENVIRONMENTAL CUES LEADING TO DISEASE AND REDUCED TREATMENT EFFECTIVENESS. THIS REVIEW PROVIDES AN OVERVIEW OF CRITICAL EPIGENETIC PROCESSES SHAPING PATHOLOGY AND PAIN, HIGHLIGHTS CURRENT RESEARCH SUPPORT FOR THE ROLE OF EPIGENOMIC MODIFICATION IN THE DEVELOPMENT OF CHRONIC PAIN, AND SUMMARIZES THE THERAPEUTIC POTENTIAL TO ALTER EPIGENETIC PROCESSES TO IMPROVE HEALTH OUTCOMES. 2013 19 2860 26 FROM SOCIAL DETERMINANTS TO SOCIAL EPIGENETICS: HEALTH GEOGRAPHIES OF CHRONIC DISEASE. SOCIAL EPIGENETICS EXPLORES RELATIONSHIPS BETWEEN SOCIAL FACTORS AND HEALTH INEQUITIES EMBODIED AT THE MOLECULAR LEVEL. THROUGH MODULATING GENE EXPRESSION, EPIGENETIC CHANGES RESULTING FROM HUMAN-ENVIRONMENT INTERACTIONS MAY PLAY A ROLE IN SHAPING HEALTH TRAJECTORIES. THIS PAPER APPLIES A HEALTH GEOGRAPHY LENS TO EXPLORE THE POTENTIAL AND SUPPORT FOR CONDUCTING SOCIAL EPIGENETIC STUDIES OF CHRONIC DISEASES WITH COMPLEX AND DYNAMIC ETIOLOGIES. IN SO DOING, WE ARGUE THAT SOCIAL EPIGENETICS PRESENTS A NOVEL SPACE FOR INVESTIGATIONS OF HEALTH AND DISEASE THAT IS TRANSDISCIPLINARY AND BUILDS UPON NEW UNDERSTANDINGS OF BODIES AND PLACE-BASED EXPERIENCES. GIVEN GENDER DISPARITIES IN CHRONIC DISEASES, WE ADOPT A FEMINIST PERSPECTIVE THAT COGITATES THE TRANSACTIVE RELATIONSHIPS BETWEEN GENDER AND HEALTH/ILL-HEALTH AS MEDIATED BY BIOSOCIAL PROCESSES AT A VARIETY OF SCALES. LOOKING FORWARD TO THE PRACTICAL UNDERTAKING OF SOCIAL EPIGENETIC STUDIES, WE ASSESS EXISTING THEORETICAL AND METHODOLOGICAL SUPPORT AS WELL AS INSIGHTS TO BE GAINED. REFLECTING UPON THE CENTRAL TENETS OF HEALTH GEOGRAPHY, WE PROPOSE A UNIQUE POSITIONALITY FOR HEALTH GEOGRAPHERS TO DRIVE THIS FIELD FORWARD. 2021 20 1290 27 DECODING THE GENETIC AND EPIGENETIC BASIS OF ASTHMA. ASTHMA IS A COMPLEX AND HETEROGENEOUS CHRONIC INFLAMMATORY DISEASE OF THE AIRWAYS. ALONGSIDE ENVIRONMENTAL FACTORS, ASTHMA SUSCEPTIBILITY IS STRONGLY INFLUENCED BY GENETICS. GIVEN ITS HIGH PREVALENCE AND OUR INCOMPLETE UNDERSTANDING OF THE MECHANISMS UNDERLYING DISEASE SUSCEPTIBILITY, ASTHMA IS FREQUENTLY STUDIED IN GENOME-WIDE ASSOCIATION STUDIES (GWAS), WHICH HAVE IDENTIFIED THOUSANDS OF GENETIC VARIANTS ASSOCIATED WITH ASTHMA DEVELOPMENT. VIRTUALLY ALL THESE GENETIC VARIANTS RESIDE IN NON-CODING GENOMIC REGIONS, WHICH HAS OBSCURED THE FUNCTIONAL IMPACT OF ASTHMA-ASSOCIATED VARIANTS AND THEIR TRANSLATION INTO DISEASE-RELEVANT MECHANISMS. RECENT ADVANCES IN GENOMICS TECHNOLOGY AND EPIGENETICS NOW OFFER METHODS TO LINK GENETIC VARIANTS TO GENE REGULATORY ELEMENTS EMBEDDED WITHIN NON-CODING REGIONS, WHICH HAVE STARTED TO UNRAVEL THE MOLECULAR MECHANISMS UNDERLYING THE COMPLEX (EPI)GENETICS OF ASTHMA. HERE, WE PROVIDE AN INTEGRATED OVERVIEW OF (EPI)GENETIC VARIANTS ASSOCIATED WITH ASTHMA, FOCUSING ON EFFORTS TO LINK THESE DISEASE ASSOCIATIONS TO BIOLOGICAL INSIGHT INTO ASTHMA PATHOPHYSIOLOGY USING STATE-OF-THE-ART GENOMICS METHODOLOGY. FINALLY, WE PROVIDE A PERSPECTIVE AS TO HOW DECODING THE GENETIC AND EPIGENETIC BASIS OF ASTHMA HAS THE POTENTIAL TO TRANSFORM CLINICAL MANAGEMENT OF ASTHMA AND TO PREDICT THE RISK OF ASTHMA DEVELOPMENT. 2023